NEW YORK (TheStreet) -- Biotech, biotech, biotech. That's been the talk of Wall Street for all of 2013, with mergers and acquisitions happening every other day. That's why TheStreet's Jim Cramer and "Mad Money" Research Director Nicole Urken discussed which biotechs could be the next to merge.
Cramer still expects a company to bid for Alexion Pharmaceuticals (ALXN).
He added that while there are a lot of IPOs coming to the market, he continues to like the "four horsemen," of which he means Celgene (CELG), Regeneron Pharmaceuticals (REGN), Gilead Sciences (GILD), and Biogen (BIIB).Biotech has been hot for several reason, Urken said, citing an improved Food and Drug Administration process, a more risk-absorbing investor base and a stronger pipeline of products. Also, these companies continue to grow at strong rates without the macro headwinds slowing them down. Specifically, Cramer said there's one company in the sector he really loves: Celgene. The company has a ton of products in its pipeline and is actually cheap when looking at it on a valuation basis. He also said Gilead Sciences could be a good company to look at it if its hepatitis-C drug pans out the way some are expecting. -- Written by Bret Kenwell in Petoskey, Mich. Follow @BretKenwell
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV